A co-author of the study said that "the presence or absence of the biomarker can now be used as a diagnostic test to identify which patients will benefit from this drug," and added that their approach can be used to screen the efficacy of any drug for any disease.
Sequenom also said that it amended its license with Isis Innovation for IP underlying its SEQureDx Down syndrome test, which the firm continues to develop following an investigation into mishandled R&D test data and results.
The study is noteworthy because the researchers were able to identify all four bases of DNA in a heteropolymeric background of DNA immobilized inside the pore, according to senior author Hagan Bayley, a professor of chemistry at Oxford.
The research, published online Sunday in Nature Nanotechnology, is the first to show that scientists can detect unlabeled single DNA bases "to a confidence level … appropriate for a highly competitive commercial sequencing system," Oxford Nanopore's CEO said.
In a paper appearing online in Nature Nanotechnology yesterday, researchers from Oxford Nanopore and the University of Oxford showed that they can accurately distinguish between nucleic acids using protein nanopores coupled to a detection system.